SCHEMBL2397413

SCHEMBL2397413

O=C1Nc2nc(Cl)ccc2C2(Cc3ccc([N+](=O)[O-])cc3C2)O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.38
C1R P00736 1/20 0.35
PNMT P11086 5/20 0.34
ADRA2A P08913 3/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
NPY5R Q15761 1/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33
TYMS P04818 1/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
LMNA P02545 1/20 0.32
RAB9A P51151 1/20 0.32
TLR9 Q9NR96 1/20 0.32
CYP3A4 P08684 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12264350 0.87 PNMT (0.38) TDP2C1RPNMTADRA2ANPY5R
SCHEMBL15583085 0.82 AVPR1A (0.35)
SCHEMBL16591475 0.80 TDP2 (0.40) TDP2PNMTADRA2ACA12CA1
SCHEMBL21900260 0.65 KCNH2 (0.39) NPY5R
SCHEMBL22271650 0.63 TDP2 (0.49) TDP2PNMTADRA2ACA12CA1
SCHEMBL261045 0.63 TDP2 (0.39) TDP2PNMTADRA2AADRA2BADRA2C
SCHEMBL3705905 0.63 TDP2 (0.49) TDP2PNMTADRA2ACA12CA1
SCHEMBL260824 0.62 CRBN (0.53) TDP2PNMTADRA2ACA12CA1
SCHEMBL5917126 0.62 CA1 (0.47) TDP2PNMTADRA2ACA12CA1
SCHEMBL379349 0.61 TDP2 (0.48) TDP2PNMTADRA2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150087641-A1 HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. 2015-03-26 US disclosed
EP-2340025-B1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2014-10-15 EP disclosed
WO-2013169565-A1 HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2013-11-14 WO disclosed
US-20110224201-A1 CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224201-A1 CGRP RECEPTOR ANTAGONISTS CCKAR, CALCRL, QRFPR TDP2 3422/4885C1R 74/4885PNMT 2532/4885
US-20150087641-A1 HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS CCKBR, CALCRL, BDKRB2 TDP2 2128/4885C1R 304/4885PNMT 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.